GO
Loading...

MorphoSys Receives Additional Patents on Novel Antibody Platform Ylanthia in the US and First Patent in China

MARTINSRIED / MUNICH, Germany, July 18, 2014 (GLOBE NEWSWIRE) -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today announced that the US Patent and Trademark Office (USPTO) and the State Intellectual Property Office of China have granted additional patents covering the Company's latest antibody platform Ylanthia.

"Our new antibody platform Ylanthia is being used in a rising number of therapeutic relationships including our recent alliances with Merck Serono and Temple University. In addition to building a track record on the commercial side, robust patent protection is important for our new technology platform and today's patents further strengthen our position around Ylanthia in our core markets and in the emerging markets," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.

The newly granted US patents (US 8,685,896 and US 8,728,981) cover an antibody library with superior biophysical properties and methods of selecting antibodies from such a library. Similar subject matter is covered in the new Chinese patent (ZL 2010 8 0022793.7). The patents have scheduled expiry dates of 2030 and 2031.

MorphoSys's Ylanthia antibody library comprises more than 100 billion distinct, fully human antibodies, which makes it the industry's largest known antibody Fab library. It uses 36 fixed, naturally-occurring heavy and light chain framework combinations, which translates into unprecedented structural diversity. The library's diversity is expected to result in antibodies against previously inaccessible target molecules and in unique epitope coverage.

Ylanthia's antibody frameworks were pre-selected for favorable expression levels, stability and aggregation behavior. A shift towards higher stability and stress tolerance will increase shelf life and serum stability of resulting antibody products, making them more cost-effective to produce and administer. A higher solubility in turn opens up the path for more convenient ways of administration, to the benefit of patients. When needed, antibodies from the Ylanthia library are optimized using MorphoSys's proprietary Slonomics technology. Slonomics enables optimization of Ylanthia antibodies with unprecedented speed and flexibility.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia® and 100 billion high potentials® are registered trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR

Mario Brkulj
Associate Director Corporate Communications & IR

Alexandra Goller
Specialist Corporate Communications & IR

Jessica Rush
Specialist Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

Media Release (PDF) http://hugin.info/130295/R/1829491/634362.pdf

HUG#1829491

Source:MorphoSys AG